PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE
The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.
1 - 12 . (canceled)
13 . A compound of the following formula:
wherein,
X is Carbon;
R 1 is phenyl, benzyl, methyl, ethyl, propyl, pyrimidine, 3,4-dimethylphenyl, 3-chloropyridazine, 2,4-dimethylpyrimidine, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, CH 2 CF 3 , 4-trifluoromethylphenyl, 4-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 4-methylphenyl, 4-methoxyphenyl, 4-chloro-2-methylphenyl, 4-fluorophenyl, 4-sulfonamidophenyl, 3-methoxyphenyl, 4-chlorophenyl, 3-chlorophenyl, 3,5-difluorophenyl, 4-aminophenyl, CH 2 CH 2 OH, ethanol, or 3,4-methylenedioxyphenyl;
R 2 is methyl, pyridine, pyridine-1-oxide, 3-cyanophenyl, 3-aminophenyl, 3-amidinophenyl, 3-dimethylaminophenyl, 2-methylthiazole, 4-methylthiadiazole, thiadiazole, 5-methylisoxazole, 1,3-dimethylpyrazole, pyrazine, pyrimidine, 5-methylimidazole, 5-methylpyrazole, 2-benzylsulfanylpyridine, 6-benzylsulfanylpyridine, CH 2 COOH, N(CH 3 ) 2 , CH 2 CH 2 SCH 3 or CH 2 -piperidinyl;
R 3 is absent, H, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , CH 2 CH 2 N(CH 3 ) 2 , CH 2 CH 2 NHCH 3 , CH 2 OH, (CH 2 ) 3 OH, CH 2 CH 2 CO 2 H, CH 2 CO 2 H, CH 2 CH 2 SOCH 3 , CH 2 CH 2 SO 2 CH 3 , CH 2 CH 2 SH or CH 2 CH 2 SCH 3 ;
R 4 is absent, H, NH 2 , CON(CH 3 ) 2 , CO 2 H, CN, CH 2 OH, CONH 2 , CSNH 2 , CONHOH, C(NH)NH 2 , CONHNH 2 , CONHCH 3 , CH 2 OCH 3 , CONH-cyclohexyl, CO 2 CH 3 ,
R 5 is isopropyl, benzyl, 4-trifluoromethylbenzyl, 4-cyanobenzyl, 4-benzoylbenzyl, 3-chlorobenzyl, pentafluorobenzyl, 3,4-dichlorobenzyl, 2-fluorobenzyl, 4-methoxybenzyl, CH 2 CH 2 -phenyl, 4-fluorobenzyl, 4-phenylbenzyl, CH 2 -imidazole, CH 2 COOH, CH 2 CH 2 COOH, (CH 2 ) 4 NH 2 , CH 2 CH 2 SCH 3 , 4-hydroxybenzyl, CH 2 -naphthyl, 4-methylbenzyl, CH 2 -indole, CH 2 -thiophene, CH 2 -cyclohexane, 4-chlorobenzyl, phenyl, 2-hydroxybenzyl, 4-tertbutoxybenzyl, CH 2 -benzylimidazole, 4-aminobenzyl, CH 2 -pyrid-3-yl, CH 2 -pyrid-2-yl, CH 2 OH, (CH 2 ) 3 NHC(NH)NH 2 or CH 2 CH(CH 3 ) 2 ; and,
R 6 is H, methyl, ethyl, propyl, isopropyl, CH 2 CO 2 H, CH 2 CO 2 Et, benzyl, or CH 2 -(2-methoxynaphthyl); or,
R 5 and R 6 together form:
14 . A pharmaceutical composition comprising a compound of claim 13 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.
15 . A compound having a chemical structure selected from the group consisting of:
16 . A pharmaceutical composition comprising a compound of claim 15 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.
17 . A compound according to claim 13 , having the structure:
18 . A compound according to claim 13 , having the structure:
19 . A compound according to claim 13 , having the structure:
20 . A compound according to claim 13 , having the structure:
21 . A compound according to claim 13 , having the structure:
22 . A compound according to claim 13 , having the structure:
23 . A compound according to claim 13 , having the structure:
24 . A compound according to claim 13 , having the structure:
25 . A compound according to claim 13 , having the structure:
26 . A compound according to claim 13 , having the structure:
27 . A compound according to claim 13 , having the structure:
28 . A compound according to claim 13 , having the structure:
29 . A compound according to claim 13 , having the structure: